Seller record · Telehealth service

VyrarX

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S4, compounding disclosure: No page says the semaglutide and tirzepatide are compounded or that they are not FDA-approved. The only answer on regulation says its pharmacies are licensed by state boards or registered with the FDA. 2 more criteria also fail; see the table below.

At a glance

VyrarXTelehealth service

5/8criteria passed

Price: Semaglutide program from $179 a month; tirzepatide program from $329
Sells: semaglutide, tirzepatide, tretinoin, and 1 more
FDA letters: None on file

Visit VyrarX See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling semaglutide and tirzepatide programs, prescription skin care and NAD+, reviewed by licensed U.S. physicians after a short medical questionnaire. It names a pharmacy and a provider network but no postal address, and never says whether its medications are compounded.

Operating entity vyrarx, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	VyrarX's website; VyrarX's terms
S2	Prescription gating	PASS	VyrarX's website; VyrarX's terms
S3	Pharmacy identification	PASS	VyrarX's website
S4	Compounding disclosure	FAIL	VyrarX's website; VyrarX's terms
S5	Analytical documentation	FAIL	VyrarX's website; VyrarX's terms; VyrarX's privacy page
S6	Business address	FAIL	VyrarX's website; VyrarX's terms; VyrarX's refund page; VyrarX's privacy page
S7	Price disclosure	PASS	VyrarX's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed U.S. physician reviews each medical questionnaire within 24 hours, and the terms say a prescription is at the sole discretion of the prescribing provider. The answer on its provider network names Locum Tele.Source: VyrarX's website; VyrarX's terms.

S2PASSThe steps list a five-minute medical questionnaire first, then a physician's review, then the plan and shipping, and the terms say fees are shown before a transaction is completed.Source: VyrarX's website; VyrarX's terms.

S3PASSThe answer to the question on who its pharmacies are names Rush Pharmacy.Source: VyrarX's website.

S4FAILNo page says the semaglutide and tirzepatide are compounded or that they are not FDA-approved. The only answer on regulation says its pharmacies are licensed by state boards or registered with the FDA.Source: VyrarX's website; VyrarX's terms.

S5FAILNo certificate of analysis or lot document is published on the home page, in the terms or in the privacy policy.Source: VyrarX's website; VyrarX's terms; VyrarX's privacy page.

S6FAILNo postal address appears on the home page, in the terms, in the refund policy or in the privacy policy, which name vyrarx, Inc. and Delaware law and give only email addresses.Source: VyrarX's website; VyrarX's terms; VyrarX's refund page; VyrarX's privacy page.

S7PASSThe semaglutide program costs from $179 a month and the tirzepatide program from $329 a month.Source: VyrarX's website.

S8PASSNo FDA warning letter names VyrarX or vyrarx, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide, tretinoin, NAD+.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells NAD+

Visit VyrarX

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.